Stocklytics Platform
Asset logo for symbol ADMA
ADMA Biologics
ADMA
86
$10.62arrow_drop_up1.72%$0.18
High Quality
High Growth

Performance History

Chart placeholder
Key Stats
Open$10.43
Prev. Close$10.44
EPS-0.02
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$2.50B
PE Ratio-
LOWHIGH
Day Range10.43
10.88
52 Week Range3.06
10.88
Ratios
P/B Ratio10.16
Revenue$258.21M
Operating M. %26.65%
Earnings$0.00
Earnings Growth %57.15%
EBITDA Margin %21.48%
ROE %-2.43%
EPS-0.02

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Correlated Companies

Price$891.46
Perf. (24h)
arrow_drop_up0.72%$6.45
Market Cap$834.88B
Price$489.80
Perf. (24h)
arrow_drop_up1.81%$8.75
Market Cap$451.06B
Price$145.64
Perf. (24h)
arrow_drop_down0.20%-$0.30
Market Cap$350.26B
Price$127.99
Perf. (24h)
arrow_drop_up0.38%$0.49
Market Cap$327.94B

About ADMA Biologics (ADMA)

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Adam S. Grossman
Headquarters
Ramsey
Employees
617
Exchange
NASDAQ
add ADMA Biologics  to watchlist

Keep an eye on ADMA Biologics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is ADMA Biologics 's (ADMA) price per share?

The current price per share for ADMA Biologics (ADMA) is $10.62. The stock has seen a price change of $0.18 recently, indicating a 1.72% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for ADMA Biologics (ADMA)?

For ADMA Biologics (ADMA), the 52-week high is $10.88, which is 2.45% from the current price. The 52-week low is $3.06, the current price is 247.06% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is ADMA Biologics (ADMA) a growth stock?

ADMA Biologics (ADMA) has shown an average price growth of 0.41% over the past three years. It has received a score of 92 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ADMA Biologics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is ADMA Biologics (ADMA) stock price performance year to date (YTD)?

As of the latest data, ADMA Biologics (ADMA) has a year-to-date price change of 133.41%. Over the past month, the stock has experienced a price change of 12.86%. Over the last three months, the change has been 78.79%. Over the past six months, the figure is 156.52%. Looking at a longer horizon, the five-year price change stands at 183.2%.

help
Is ADMA Biologics (ADMA) a profitable company?

ADMA Biologics (ADMA) has a net income of -$28.24M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 34.16% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 26.65% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $258.21M, with a revenue growth rate of 67.59%, providing insight into the company's sales performance and growth. The gross profit is $88.22M. Operating income is noted at $21.63M. Furthermore, the EBITDA is $54.22M.

help
What is the market capitalization of ADMA Biologics (ADMA)?

ADMA Biologics (ADMA) has a market capitalization of $2.5B. The average daily trading volume is 2.65M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level